Plus Therapeutics, Inc.
PSTVNASDAQHealthcare● Active
$5.53
+$0.12(+2.22%)
Market Cap$13380410
P/E Ratio—
52W High$23.5
52W Low$2.9
Plus Therapeutics, Inc. (PSTV) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PSTV · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$1.05
Est. -$0.95 · -10.5%
Revenue
$0.00B
Est. $0.00B · +5.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
PSTV reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.95 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 15, 2026 | -$0.95 | -$1.05 | -10.5% | $0.00B | $0.00B | +5.5% |
| ▼ Q1 FY2026 | Mar 12, 2026 | -$0.80 | -$0.83 | -4.2% | $0.00B | $0.00B | +10.6% |
| ▼ Q4 FY2025 | Oct 30, 2025 | -$0.02 | -$0.04 | -100.0% | $0.00B | $0.00B | -6.5% |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.09 | -$0.01 | +88.9% | $0.00B | $0.00B | -6.5% |
| ▼ Q2 FY2025 | May 30, 2025 | -$0.25 | -$0.56 | -125.7% | $0.00B | $0.00B | -28.6% |
| ▼ Q1 FY2025 | Mar 27, 2025 | -$0.51 | -$0.67 | -31.4% | $0.00B | $0.00B | -6.4% |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$0.56 | -$0.37 | +34.2% | $0.00B | $0.00B | -0.7% |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.95
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Miss
EPS Actual
-$1.05
EPS Est.
-$0.95
EPS Surpr.
-10.5%
Revenue
$0.00B
Q1 FY2026
Mar 12, 2026Miss
EPS Actual
-$0.83
EPS Est.
-$0.80
EPS Surpr.
-4.2%
Revenue
$0.00B
Q4 FY2025
Oct 30, 2025Miss
EPS Actual
-$0.04
EPS Est.
-$0.02
EPS Surpr.
-100.0%
Revenue
$0.00B
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.01
EPS Est.
-$0.09
EPS Surpr.
+88.9%
Revenue
$0.00B
Q2 FY2025
May 30, 2025Miss
EPS Actual
-$0.56
EPS Est.
-$0.25
EPS Surpr.
-125.7%
Revenue
$0.00B
Q1 FY2025
Mar 27, 2025Miss
EPS Actual
-$0.67
EPS Est.
-$0.51
EPS Surpr.
-31.4%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$0.37
EPS Est.
-$0.56
EPS Surpr.
+34.2%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.90 | $-0.64 | $-0.42 | 1 |
| Q3 FY2028 | $-1.26 | $-0.89 | $-0.58 | 1 |
| Q2 FY2028 | $-1.21 | $-0.86 | $-0.56 | 1 |
| Q1 FY2028 | $-1.47 | $-1.04 | $-0.68 | 1 |
| Q4 FY2027 | $-0.78 | $-0.56 | $-0.36 | 1 |
| Q3 FY2027 | $-0.77 | $-0.55 | $-0.36 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 15, 2026 | -10.5% | $5.76 | $5.25 | -8.85% |
| ▼ Q1 FY2026 | Mar 12, 2026 | -4.2% | $7.69 | $7.37 | -4.16% |
| ▼ Q4 FY2025 | Oct 30, 2025 | -100.0% | $13.54 | $13.25 | -2.14% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +88.9% | $14.36 | $13.56 | -5.57% |
| ▼ Q2 FY2025 | May 30, 2025 | -125.7% | $7.16 | $7.17 | +0.14% |
| ▼ Q1 FY2025 | Mar 27, 2025 | -31.4% | $36.75 | $38.00 | +3.40% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +34.2% | $32.75 | $31.50 | -3.82% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -34.0% | $37.25 | $35.50 | -4.70% |
Q2 FY2026-8.85%
Report Date
May 15, 2026
EPS Beat/Miss
-10.5%
Price Before
$5.76
Price After
$5.25
Q1 FY2026-4.16%
Report Date
Mar 12, 2026
EPS Beat/Miss
-4.2%
Price Before
$7.69
Price After
$7.37
Q4 FY2025-2.14%
Report Date
Oct 30, 2025
EPS Beat/Miss
-100.0%
Price Before
$13.54
Price After
$13.25
Q3 FY2025-5.57%
Report Date
Aug 14, 2025
EPS Beat/Miss
+88.9%
Price Before
$14.36
Price After
$13.56
Q2 FY2025+0.14%
Report Date
May 30, 2025
EPS Beat/Miss
-125.7%
Price Before
$7.16
Price After
$7.17
Q1 FY2025+3.40%
Report Date
Mar 27, 2025
EPS Beat/Miss
-31.4%
Price Before
$36.75
Price After
$38.00
Q4 FY2024-3.82%
Report Date
Nov 14, 2024
EPS Beat/Miss
+34.2%
Price Before
$32.75
Price After
$31.50
Q3 FY2024-4.70%
Report Date
Aug 14, 2024
EPS Beat/Miss
-34.0%
Price Before
$37.25
Price After
$35.50
Avg Beat Reaction-4.70%
Avg Miss Reaction-2.72%
Beat Rate2 / 8 quarters
Largest Move-8.85% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PSTV ends December
Plus Therapeutics, Inc. (PSTV) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-1.05 — missing the analyst consensus of $-0.95 by -10.5%. The next PSTV earnings date is expected around September 1, 2026.
Each quarter, investors track PSTV earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PSTV revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PSTV's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PSTV earnings · 5 questionsPlus Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. PSTV typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PSTV historically reports after market close (AMC).
PSTV earnings datewhen is PSTV earningsPSTV next earnings datewhen does PSTV report earningsPSTV earnings calendar
▸ Source: FMP · Plus Therapeutics, Inc. SEC filings · US GAAP · Plus Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026